ESTaid Corp. (KOSDAQ:239340)
South Korea · Delayed Price · Currency is KRW 2,380.00
-60.00 (-2.46%)
Last updated: Aug 6, 2025
Ligand Pharmaceuticals Revenue
ESTaid had revenue of 4.84B KRW in the quarter ending March 31, 2025, with 6.68% growth. This brings the company's revenue in the last twelve months to 16.70B, up 21.63% year-over-year. In the year 2024, ESTaid had annual revenue of 16.40B with 18.51% growth.
Revenue (ttm)
16.70B
Revenue Growth
+21.63%
P/S Ratio
3.70
Revenue / Employee
260.96M
Employees
64
Market Cap
61.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.40B | 2.56B | 18.51% |
| Dec 31, 2023 | 13.84B | -9.08B | -39.63% |
| Dec 31, 2022 | 22.92B | -5.86B | -20.36% |
| Dec 31, 2021 | 28.78B | 4.97B | 20.85% |
| Dec 31, 2020 | 23.81B | -865.73M | -3.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Electronics | 308.59T |
| SK hynix | 77.21T |
| LG Energy Solution | 25.76T |
| Samsung Biologics | 4,898.69B |
| Hanwha Aerospace | 15.28T |
| Hyundai Motor Company | 178.98T |
| Doosan Enerbility | 15.88T |
| HD Hyundai Heavy Industries | 15.32T |